Vivos Completes Planned Dosing Schedule for Feline Sarcoma Program
January 12 2018 - 2:20PM
Richland, WA, Jan. 12, 2018 (GLOBE NEWSWIRE) --
Vivos Inc (OTC: RDGL) announced today that it has completed its
planned dosing schedule to determine the effectiveness of using the
Company’s proprietary RadioGel™ therapy to treat feline
sarcoma.
An initial study of two cats was completed in September 2017 at
Washington State University (WSU). The results of that study
indicated RadioGel performed as
designed, confirming objective response (destruction of tumor
tissue) without any negative or detrimental side-effects.
Subsequently, an additional three cats with advanced cases of
sarcoma were treated, two in December 2017 and one in January 2018.
As planned, the additional treatment program was completed at
higher radiation doses to optimize levels for therapy.
Dosimetry calculations show that lethal doses to the cancer
cells will occur over the first ten days, after which, less than 5%
of the radiation will remain in the animals. It will take
approximately three months for the biopsy and follow-up analysis to
further confirm the effectiveness of the therapy.
The final report from these studies will be shared with VCA as
part of the Company’s continuing discussions about a business
relationship in private veterinarian clinics.
The next step will be to generate data on the treatment of
canine sarcoma at the University of Missouri. These data will also
be shared with the private clinic consortiums and with the FDA as
part of the Company’s pre-clinical testing for the use of RadioGel
in humans.
Mike Korenko, CEO of Vivos, stated, “We want to thank our
shareholders for the continued support and patience as we execute
methodically on the plan we outlined in the fall. A disciplined
approach is the best way to succeed in this highly regulated
environment, and we continue to make meaningful steps forward
toward our goals.”
About Vivos Inc. (OTC: RDGL)
The strategic market sector of RDGL is isotope
applications. Currently, the Company is engaged in the
development of RadioGelTM, an Yttrium-90 based
brachytherapy device, for the treatment of tumors. Brachytherapy
uses radiation to destroy cancerous tumors by placing a radioactive
isotope inside the treatment area.
The Company is engaging the FDA for permission to use
RadioGelTM for the treatment of advanced basal and
squamous cell skin cancers. The IsoPet Solutions division of RDGL
is focused on demonstrating the safety and therapeutic
effectiveness for different animal cancers in four different
university veterinary hospitals. RDGL is positioning itself so that
after this demonstration phase, The Company can begin to generate
revenues through the sale of RadioGelTM to private
animal clinics.
The Company currently is outsourcing material aspects of
manufacturing of its product in the United States and intends to
enter into licensing arrangements outside of the United States for
the manufacturing and distribution of RadioGelTM in
other countries.
About RadioGel™
RadioGelTM is a hydrogel liquid containing tiny
Yttrium-90 phosphate particles to be injected into a tumor.
This hydrogel is a liquid at temperatures below body temperature
but begins to gel, harden, upon injection as the temperature
increases to normal body temperature, thereby locking the particles
in place. The particles emit a very high concentrated and contained
beta irradiation to kill the tumor. The beta radiation has a short
penetration distance so there is minimal collateral damage to
healthy tissues outside of the injected area.
RadioGelTM also has a short half-life – delivering
more than 90% of its therapeutic radiation within 10 days.
This compares favorably to other available treatment options
requiring up to 6 weeks or more to deliver a full course of
radiation therapy. This is an outpatient treatment much safer to
the personnel treating the patient than competing brands and the
patient can go home immediately with no risk to family members.
http://www.globenewswire.com/NewsRoom/AttachmentNg/76780003-3f5d-44b3-976b-092846ce97e5
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
You can identify these statements by the use of the words "may,"
"will," "should," "plans," "expects," "anticipates," "continue,"
"estimates," "projects," "intends," and similar expressions.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those projected or
anticipated. These risks and uncertainties include, but are not
limited to, the Company's ability to successfully execute its
expanded business strategy, including by entering into definitive
agreements with suppliers, commercial partners and customers;
general economic and business conditions, effects of continued
geopolitical unrest and regional conflicts, competition, changes in
technology and methods of marketing, delays in completing various
engineering and manufacturing programs, changes in customer order
patterns, changes in product mix, continued success in technical
advances and delivering technological innovations, shortages in
components, production delays due to performance quality issues
with outsourced components, regulatory requirements and the ability
to meet them, government agency rules and changes, and various
other factors beyond the Company's control.
We have changed our email and website to reflect our focus on
RadioGelTM. Please visit our website located
at www.radiogel.com, which contains a direct link to recent
presentations and interviews at
https://www.redchip.com/company/Biotech/ADMD/376/admd.
CONTACT:
Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com
509-736-4000
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Apr 2023 to Apr 2024